# HARNESSING HOST RESPONSE TO PREVENT MYELOMA

> **NIH NIH R35** · EMORY UNIVERSITY · 2022 · $913,781

## Abstract

Summary
In spite of major therapeutic advances there is an unmet need to gain fundamental
insights into the pathogenesis of myeloma (MM) and develop newer approaches to
prevent clinical malignancy. Our research program will build on our prior efforts in two
areas- understanding the etio-pathogenesis of myeloma and harnessing host response
to prevent cancer. In recent studies, we have discovered that chronic activation by
lysolipids underlies the etiology of MM in nearly a third of patients. We have also
developed new humanized mouse models that span the entire spectrum of malignancy,
including precursor states. These advances set the stage for next studies to better
understand how lipid-mediated inflammation may drive the development of myeloma and
how to prevent it. Understanding these pathways may have implications for mechanisms
underlying lipid-mediated inflammation in diverse states including obesity. MM and its
precursor states are also an important model to probe basic questions about how to
harness the biology of both adaptive and innate immune system to prevent cancer.

## Key facts

- **NIH application ID:** 10480937
- **Project number:** 5R35CA197603-07
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** MADHAV V DHODAPKAR
- **Activity code:** R35 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $913,781
- **Award type:** 5
- **Project period:** 2016-08-01 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10480937

## Citation

> US National Institutes of Health, RePORTER application 10480937, HARNESSING HOST RESPONSE TO PREVENT MYELOMA (5R35CA197603-07). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10480937. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*